Compare SPHL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPHL | APRE |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 5.7M |
| IPO Year | 2023 | 2019 |
| Metric | SPHL | APRE |
|---|---|---|
| Price | $2.30 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | ★ 2.2M | 144.6K |
| Earning Date | 09-23-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.41 |
| 52 Week High | $25.11 | $1.49 |
| Indicator | SPHL | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 42.04 |
| Support Level | N/A | $0.41 |
| Resistance Level | $2.98 | $0.81 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 0.27 | 52.63 |
Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.